Gastroenterology
Page 1 • 3 itemsGlobal pharma market insights for gastroenterology: track drug development, regulatory approvals, and M&A for IBD, liver disease, and GI oncology.
mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026
New clinical trial data validates mBIOTA Elemental as effective IBS therapeutic, showing symptom improvement across all three IBS subtypes at DDW 2026.
RedHill's RHB-204 Shows Comparable Efficacy to RHB-104 in Crohn's Disease MAP Treatment Development
RedHill's next-generation RHB-204 demonstrates comparable MAP-killing efficacy to RHB-104, advancing development for Crohn's disease treatment.
Dr. Falk Pharma and Renexxion Announce Naronapride Phase 2b Gastroparesis Results at DDW 2026
Dr. Falk Pharma and Renexxion present Phase 2b MOVE-IT study results for naronapride in gastroparesis treatment at Digestive Disease Week 2026.